PPIDT00295
Drug Information
| Name | Atezolizumab |
|---|---|
| Sequence | EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB11595 |
| Type | biotech |
| Indication | Atezolizumab has approved indications for the following conditions:[L44336] **Non-Small Cell Lung Cancer (NSCLC)** - as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumours have PD-L1 expression on ≥ 1% of tumour cells, as determined by an FDA-approved test. - for the first-line treatment of adult patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained ≥ 50% of tumour cells [TC ≥ 50%] or PD-L1 stained tumour-infiltrating immune cells [IC] covering ≥ 10% of the tumour area [IC ≥ 10%]), as determined by an FDAapproved test, with no EGFR or ALK genomic tumour aberrations. - in combination with [bevacizumab], [paclitaxel], and [carboplatin], for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumour aberrations. - in combination with paclitaxel protein-bound and carboplatin for the firstline treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. - for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have disease progression on FDA-approved therapy for NSCLC harbouring these aberrations prior to receiving atezolizumab. **Small Cell Lung Cancer (SCLC)** - in combination with carboplatin and [etoposide], for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). **Hepatocellular Carcinoma (HCC)** - in combination with bevacizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy. **Melanoma** - in combination with [cobimetinib] and [vemurafenib] for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. **Alveolar Soft Part Sarcoma (ASPS)** - for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic ASPS. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Intravenous |
1200 mg/20mL
|
| Injection, solution | Intravenous |
840 mg/14mL
|
| Injection, solution | Subcutaneous |
1875 mg
|
| Injection, solution, concentrate | Intravenous |
1200 mg/20ml
|
| Injection, solution, concentrate | Intravenous |
1200 mg
|
| Injection, solution, concentrate | Intravenous |
60 mg/1ml
|
| Injection, solution, concentrate | Intravenous |
840 mg
|
| Injection, solution, concentrate | Intravenous; Parenteral |
1200 MG
|
| Injection, solution, concentrate | Intravenous; Parenteral |
840 MG
|
| Solution | Intravenous |
1200 mg / 20 mL
|
| Solution | Intravenous |
1200.000 mg
|
| Solution | Intravenous |
840 mg / 14 mL
|
| Injection, solution, concentrate | — |
1200 mg/20ml
|
| Injection, solution, concentrate | Intravenous |
60 mg/ml
|
| Injection, solution, concentrate | — |
840 mg/14ml
|
| Solution | Intravenous |
1200 mg
|
| Solution | Intravenous |
840 mg/14ml
|
| Injection | Subcutaneous |
|
| Solution | Subcutaneous |
125 mg / mL
|
| Solution | Intravenous |
120000000 mg
|